"Medical Buyer team should be congratulated for their quality work. Overall printing and the content of this magazine are excellent, which helps us to...
Dr. Anoop Dayal
Ex-Director - Administration, Monilek Hospital, Jaipur
  • Home
  • Buyers Guide
  • Magazine
  • Contact us
  • About Us
  • Booster Dose

Magazine

Current Issue
Magazine-Archive
News
News-Archive
Advertise with Us
Subscribe

Business Directory

Browse By Category
List By Name

Search using keywords

 Buyers Guide
 Medical Buyer Website
       
Advance search

News

  • ASITECH: Where technology meets medical enterprise
  • Philips introduces advanced informatics solutions
  • Panoptes forays into security and healthcare sector
  • BPL to expand with mercury free devices
  • Covidien completes USD 2.6 billion purchase of ev3
  • Sysmex, Amerinet sign urinalysis contract
Home arrow Current Issue arrow RFCL continues to outpace market growth
RFCL continues to outpace market growth
Tuesday, 06 July 2010


On your vision for RFCL Ltd.Image

"Leveraging Science to Provide Solutions for a Better Life is our vision".

To have a clear understanding it is important to know that at RFCL we have two strategic business units-Diagnova, catering to biomedical segment and Rankem offering scientific laboratory solutions, reagents and chemicals.

Through these two verticals we provide world class products and services to healthcare professionals for in vitro diagnostics, biosciences research, medical diagnostic services as also catering to research and quality assurance requirements of pharmaceutical and biotechnology companies, leading research institutes and being the supplier of choice for manufacturing process at pharmaceuticals and photo voltaic industry.

Our vision is to build RFCL both in scale and quality and be at the forefront of the industry which is reflected in our three values - "Aiming High", "Customer Delight" and "Dream Place to Work".

On plans for the company.

Looking back at the last four years, RFCL has achieved CAGR of 40 percent vis-a-vis industry CAGR between 15-20 percent. It means we have grown at "Double the Market Growth Rate" and continually increased our market share. Of course, inorganic growth has aided RFCL but nevertheless organic growth too has been higher than the industry growth.

We have recently given a final shape to our mid-term plan "Sprint 2014" i.e. Strategic Planning for RFCL inspirational and nimble triumphs, whereby we look at 23 percent CAGR for next 4 years. This time around our focus is on "Self Reliance". As such we are investing in creating world class manufacturing asset, higher level of spend on product development, R&D, technology transfer and outsourcing R&D wherever possible.

The growth scenario in our industry offers tremendous opportunities and we have built "Leadership Band Width" at RFCL for multitasking capability and continue to outpace market growth.

Anything else you may like to add.

I am proud to share with you that RFCL has been ranked at No.2 in the biotechnology and pharmaceuticals segment, and amongst the Top 100 Great Places to Work in India in 2010 (A study done by Great Places to Work Institute, India and Economic Times).

Being named as one of the best workplaces in India, especially in the biotechnology and pharmaceuticals sector is a matter of great pride for RFCL and an important measure that our policies and practices are comparable to some of the reputed corporate leaders in India.

80 percent of employees participating in the survey indicated that RFCL is a great place to work. This is an inspiring reflection of our employees' experiences and opinions about our culture and values, their trust in the leadership, integrity and fairness, teamwork, and camaraderie at our dynamic organization.

 
< Prev   Next >
[ Back ]
Vantage Medifest 2010
 
Subscribe Medical Buyer monthly magazine

Login Form






Lost Password?
No account yet? Register
Contact us | Magazine Subscription | Advertise with Us | Careers | Site Map | About us
Privacy Policy | Disclaimer | Terms of Use | Resources
© Copyright 2007, ADI Media Private Limited.